Polymorphisms of CYP2C19 *2,*3,*17 were determined by the Spartan RX CYP2C19 and confirmed by SNP genotyping assay.  The CYP2C19 genotypes were distributed as 4 (3.3%) for UM, 39 (32.8%) for EM, 54 (45.4%) for IM, 22 (18.5%) for PM by evaluation with Spartan RX CYP2C19.  The genotyping results between Spartan RX CYP2C19 and SNP genotyping assay showed discrepancy in 2 patients. 
Spartan RX CYP2C19
The degree of platelet inhibition was assessed by the VerifyNow P2Y12 system (Accumetrics, USA).



VerifyNow P2Y12 system